secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001641172-25-000283
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte Q4 revenue $1.5M, GAAP loss $33.5M; transplant test on track for 2026 FDA authorization
--------------------------------------------------------------------------------

- Q4 2024 pharma-services revenue $1.5M; full-year $1.9M; gross margin 40%.
- GAAP loss from continuing ops $33.5M ($1.93/sh); non-GAAP operating loss $4.4M.
- Recorded $41.9M intangible impairment (DetermaCNI $35.1M, DetermaIO $6.8M) offset by $13.7M contingent consideration gain.
- Cash $10.3M at year-end; raised $29.1M in Feb 2025 offering; Bio-Rad holds ~9.66% stake.
- Targeting FDA submission for kitted transplant assay GraftAssureDx by end 2025; authorization expected 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000164117225000283/0001641172-25-000283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000164117225000283/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer